China Biologic Products Holdings (China Biologic Products Holdings) Quick Ratio : 10.13 (As of Sep. 2020)

View and export this data going back to 2001. Start your Free Trial

What is China Biologic Products Holdings Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. China Biologic Products Holdings's quick ratio for the quarter that ended in Sep. 2020 was 10.13.

China Biologic Products Holdings has a quick ratio of 10.13. It generally indicates good short-term financial strength.

The historical rank and industry rank for China Biologic Products Holdings's Quick Ratio or its related term are showing as below:

CBPO' s Quick Ratio Range Over the Past 10 Years
Min: 0.54 Med: 3.07 Max: 10.3
Current: 10.13

During the past 13 years, China Biologic Products Holdings's highest Quick Ratio was 10.30. The lowest was 0.54. And the median was 3.07.

CBPO's Quick Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.515 vs CBPO: 10.13

China Biologic Products Holdings Quick Ratio Historical Data

The historical data trend for China Biologic Products Holdings's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Biologic Products Holdings Quick Ratio Chart

China Biologic Products Holdings Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Quick Ratio

Get a 7-Day Free Trial

3.39

3.17

3.93

9.10

8.79

China Biologic Products Holdings Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Quick Ratio	Get a 7-Day Free Trial															8.44	8.79	8.86	9.50	10.13

Competitive Comparison of China Biologic Products Holdings's Quick Ratio

For the Biotechnology subindustry, China Biologic Products Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Biologic Products Holdings's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Biologic Products Holdings's Quick Ratio distribution charts can be found below:

* The bar in red indicates where China Biologic Products Holdings's Quick Ratio falls into.

China Biologic Products Holdings Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

China Biologic Products Holdings's Quick Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Quick Ratio (A: Dec. 2019 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(1299.725	-	250.728)	/	119.309
	=	8.79

China Biologic Products Holdings's Quick Ratio for the quarter that ended in Sep. 2020 is calculated as

Quick Ratio (Q: Sep. 2020 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(1494.958	-	234.465)	/	124.449
	=	10.13

China Biologic Products Holdings (NAS:CBPO) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.

China Biologic Products Holdings Quick Ratio Related Terms

Thank you for viewing the detailed overview of China Biologic Products Holdings's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

China Biologic Products Holdings (China Biologic Products Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Biologic Products Holdings Inc (NAS:CBPO) » Definitions » Quick Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Chaoyang Park Road, 18th Floor, Jialong International Building, Chaoyang District, Beijing, CHN, 100125

Website

http://www.chinabiologic.com

China Biologic Products Holdings Inc is a biopharmaceutical company principally engaged in the research, development, manufacturing and sales of human plasma-based products in China. The company operates its business through two majority owned subsidiaries, Shandong Taibang and Guizhou Taibang. China Biologic's product pipeline includes a variety of dosages across multiple product categories. Its principal products are human albumin and immunoglobulin for intravenous injection. All of the company's products are prescription medicines administered in the form of injections. China Biologic's sales model focuses on direct sales to hospitals and inoculation centers and is complemented by distributor sales.

Executives

Zhijing Cbpo Liu	officer: Corporate Vice President	19 CHAOYANG PARK ROAD 18/F, JIALONG INTERNATIONAL BUILDING BEIJING F4 100125
Sean Shao	director	21ST FLOOR, EVERBRIGHT BANK BUILDING, ZHUZILIN, FUTIAN DISTRICT, SHENZHEN, GUANGDONG F4 518040
David Gao	director, officer: Chief Executive Officer	C/ BEIJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Albert Yeung	director	C/O BEIJING MED-PHARM CORPORATION 600 WEST GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
David Hui Li	director	C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017
Min Fang	director	UNIT 2206, BUND CENTER OFFICE TOWER NO. 222 YANAN ROAD (EAST) SHANGHAI F4 200002
Zhijun Tong	director	C/O BMP SUNSTONE CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Joseph Chow	director	10110 SORRENTO VALLEY ROAD SUITE C SAN DIEGO CA 92121
Yungang Lu	director	4TH FLOOR, ZHONGDIAN INFORMATION TOWER 6 ZHONGGUANCUN S. ST., HAIDIAN DIST. BEIJING F4 100086
Warburg Pincus Llc	10 percent owner	450 LEXINGTON AVENUE, NEW YORK NY 10017
Wp X Biologics Llc	director, 10 percent owner	C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK X1 10017
Warburg Pincus X Partners, L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus Private Equity X, L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus X Gp L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus X, L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017